{
  "docId": "019de512-188f-75bd-b9c3-b699923bd74c",
  "docSlug": "b87a8eceb8fdc0b05f41052c19d68b16",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Adagio Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 19,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "comparison_table",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "The slide contrasts cocktail-based strategies (colored dots) with a single broadly neutralizing antibody (black dots) against various SARS-related coronaviruses.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de512-188f-75bd-b9c3-b699923bd74c/6",
  "deckHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c",
  "deckJsonHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c.json",
  "deckAnchorHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.32,
        "y": 0.24
      },
      "kind": "chart",
      "text": "Neutralization IC50 plot",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fe3f404-7ec7-4ece-92bb-932421d651b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.03,
        "y": 0.8
      },
      "kind": "disclaimer",
      "text": "ADG2 is the parent molecule of ADG20... There are no head-to-head trials... All trademarks are the property of their respective owners.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c225904-05a3-4db2-8c04-a67281710a87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.03,
        "y": 0.24
      },
      "kind": "image",
      "text": "Phylogenetic tree of SARS-related viruses",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13835700-7f42-4328-94e4-69487dc230e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.75,
        "y": 0.25
      },
      "kind": "list",
      "text": "Legend of antibody therapies and corporate logos",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e44f2942-0179-4eea-8f37-8233ddca5aa6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Cocktails or broadly neutralizing antibodies targeting highly conserved epitopes?",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0d0f117-c4a3-4183-ae68-62d615266796",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "How do we deal with variants: a tale of two strategies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6ebc25e-e34b-494b-9cf3-02e1bdeefe18",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "92314433-dda0-4a1b-9499-140ca1bc6ba5",
      "evidence": "Contrasts two distinct therapeutic strategies (cocktails vs broadly neutralizing antibodies)",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 5,
      "beatId": "6a1a205b-c7b3-4004-94f2-1eab1f50d86f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document agitates the problem through multiple tables and data points, highlighting the challenge of COVID-19 variants.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "367a8c0e-d39d-4694-aace-945e8b5a0e36",
      "evidence": "The document implies the cost of inaction through its emphasis on the challenge of COVID-19 variants and the need for effective treatments.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing COVID-19 variants?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}